Falling API sales and “an unprecedented negative economic environment” have forced Perrigo to cut its fiscal 2009 profit forecast and sent stock plummeting by 20 per cent.
Contract research organisation PharmaNet Development Group has found a buyer just a few weeks after saying it was considering placing itself on the block.
US contract developer Xcelience has added small-scale batch production capability to its repertoire of good manufacturing proactice (GMP) accredited production services in a bid to attract drug firms working with small quantities of API.
The EU has backed a €15.9m ($20.4m) research collaboration that will seek to develop drug delivery vehicles that can be tracked through the body with MRI and triggered using ultrasound.
A US federal appeal court has reinstated lawsuits by Nigerian families against Pfizer in a move that could have wide ranging implications for companies conducting clinical trials abroad.
Almac Sciences, part of global contracting group Almac, chose this year’s Informex in San Francisco, US to showcase its solid state chemistry (SSC) services to drugmakers in North America.
Two months after the European Union (EU) released antitrust findings the FTC is suing Solvay Pharmaceuticals and two other companies for illegally agreeing to a delay generic’s release.
As the sophistication of counterfeit drug packaging continues to improve it is becoming harder and harder to tell real products from fake. in-PharmaTechnologist spoke with Alpvision's Roland Meylan about the company's approach to brand authentication.
US contract development firm Azopharma has begun offering microdosing at its AvivoClin facility in Daytona Beach, Florida, joining market leaders like Xeleron and Covance in the Phase 0 trial sector.
Indian IT company Satyam continues to be rocked by the fraud scandal, with media reports claiming that GSK and Novartis are on the verge of taking their business elsewhere.
Within Obama’s $819bn economic stimulus package are numerous provisions relevant to the pharmaceutical industry, including funding to construct or renovate private manufacturing facilities.
Roche has stepped up its pursuit of Genentech, launching a hostile bid of $42bn after growing frustrated with the lack of progress over the past six months.
Canadian contract manufacturing organisation PharmEng International, which has been hit by dwindling cash reserves in recent months, got a boost last week when its subsidiary Keata Pharma was awarded a C$3m research grant.
Pfizer’s $68bn swoop for Wyeth looks set to start an epidemic of merger madness according to comments by Frost & Sullivan (F&S) analyst Shabeer Hussain.
Thermo Fisher Scientific hopes that the web functionality offered by the latest generation of its Darwin LIMS system will help it become the natural selection for drug makers seeking an all-in-one QA solution.
D3 Technology hopes its new SERS-based cleaning verification test, that follows FDA guidelines, will prove attractive to drugmakers looking to expedite the cleaning process and cut downtime between production runs.
ABB has launched its latest process analytical technology (PAT) software xPAT, which it claims will help companies implement quality by design (QbD) through a products entire lifecycle.
The world’s largest contract research organisation, Covance, has maintained its earnings guidance for 2009 despite a slowdown in revenue growth and lower profits in the fourth quarter of 2008.
The WHO has delayed its controversial EB 124/14 amendment that would, according to some groups, broaden the organisation’s definition of “counterfeit” from its current focus on patient health to include infringements of intellectual property.
GS1 UK has released positive preliminary results from a track and trace pilot study, which used bar codes and EPC/RFID tags to follow drugs from manufacturing plants to a hospital.
Icon has brought its operations in line with new FDA guidelines by implementing an electronic system to accelerate the adjudication of cardiovascular events in diabetes trials.
Equateq is at Informex 2009 showcasing its synthesised 98 per cent pure omega-6 DGLA, use of which has previously been restricted owing to difficulties obtaining it from natural sources.
Contract research company Parexel saw its share rocket more than 30 per cent yesterday after it reported a hike in its second quarter revenues and despite a fallback in net profits.
The US National Institutes of Health has awarded a series of new contracts to try to stimulate greater use of sophisticated data management software in small to medium-sized clinical trials.
Pfizer’s fourth quarter results saw net income plummet by 90 per cent and revealed that the company is to close five manufacturing facilities, laying-off 10 per cent of its workforce.
Novavax believes its new $5m vaccine facility, which became operational this week, shows the cost and efficiency advantages of manufacturing with disposable, single use systems.
The US Food and Drug Administration (FDA) gave the go-ahead to the first clinical trials of a stem cell-based therapy late last week, in a major boost to the development of the technology.
OutsourcingPharna.com presents a round-up of recent contracts awarded to contract development and manufacturing services companies – and finds a lot of activity in the biomanufacturing sector.
Active pharmaceutical ingredient (API) manufacturer Ash Stevens Inc has been accredited under an industry-backed scheme that certifies companies whose processes are environmentally sound and safe.
Pfizer has confirmed it has entered into an agreement to buy Wyeth in a deal worth $68bn, which it hopes will strengthen its position in anticipation of a challenging few years.
ALS Therapy Development Institute (ALS TDI) and Asklepios BioPharmaceutical have entered into a collaboration to develop viral vectors for drug delivery.
Health charity PATH has developed a formulation to stop vaccines suffering from freeze damage, which it believes will help ensure products are fully potent when they reach their destination.
Indian company Neuland Laboratories has launched a push into the peptide manufacturing sector to expand the range of active pharmaceutical ingredients (APIs) it can offer to customers.
Two US companies specialising in sleep disorders - Rem Medical and PsyPharma Global, have pooled their resources to offer research services to the pharmaceutical industry.
We spoke with Martijn Eijkenboom, president of NAF & VSM, to discuss his companies’ entry into the market for pre-washed vials, ampoules and test tubes.
Valois Pharma has informed in-PharmaTechnologist that it is developing a range of add-ons for its equadel nasal drug delivery device, which the company believes will help improve patient compliance.
UK-headquartered Premier Research Group has signed a deal to buy the assets of fellow contract research organisation (CRO) Pivotal Research Centers, a specialist in Phase I to IIa trials, for $4.75m.
A social networking tool specifically designed for patients involved in clinical trials has been set up by Acurian, a company specialising in patient recruitment services.
Preterm infants are routinely exposed to pharmaceutical excipients at levels which could potentially be toxic, according to researchers at Leicester Royal Infirmary in the UK.
A new report suggests the large numbers of fake drugs produced in China could drive CMO customers away and see Central and Eastern Europe (CEE) emerge as a contract manufacturing hotbed.
Late last week the US Department of Health and Human Services (HHS) awarded Novartis a $490m contract to continue work on its cell-culture influenza vaccine plant in Holly Springs, North Carolina, US. in-PharmaTechnologist spoke with Novartis spokesman...
Ireland’s Merrion Pharmaceuticals’ GIPET oral delivery technology platform has won the firm its second licensing agreement with Danish insulin giant Novo Nordisk.
An Indian doctor has slammed the nation’s clinical trials, claiming they use the vulnerable, the system is corrupt and that the country lacks high quality scientists.
The US Food and Drug Administration (FDA) has issued a draft guidance on the measures pharmaceutical and other manufacturers should take to make sure imported FDA-regulated products are in line with federal statutes and regulations.
Pharmaceutical Product Development of the US is expecting to post a 12 per cent hike in revenues in 2009, helped by the recent opening of offices in Ireland and Singapore and new deals with Merck & Co.
Contract research firm Covance has been given the green light for its $100m (€77m) animal testing and drug candidate development facility in Chandler, Arizona, US.
Lonza is spending $26m to expand capacity at its facility in Walkersville, Maryland, US as regulatory progress made with Osiris’ Prochymal looks set to kick start the era of cell therapies.
